Turnstone Biologics (TSBX) Competitors $0.35 +0.03 (+9.72%) Closing price 04/25/2025 03:58 PM EasternExtended Trading$0.35 0.00 (0.00%) As of 04/25/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TSBX vs. PLUR, INKT, MRNS, ALXO, FGEN, ATHE, ALGS, ESLA, ALLK, and BRNSShould you be buying Turnstone Biologics stock or one of its competitors? The main competitors of Turnstone Biologics include Pluri (PLUR), MiNK Therapeutics (INKT), Marinus Pharmaceuticals (MRNS), ALX Oncology (ALXO), FibroGen (FGEN), Alterity Therapeutics (ATHE), Aligos Therapeutics (ALGS), Estrella Immunopharma (ESLA), Allakos (ALLK), and Barinthus Biotherapeutics (BRNS). These companies are all part of the "pharmaceutical products" industry. Turnstone Biologics vs. Pluri MiNK Therapeutics Marinus Pharmaceuticals ALX Oncology FibroGen Alterity Therapeutics Aligos Therapeutics Estrella Immunopharma Allakos Barinthus Biotherapeutics Turnstone Biologics (NASDAQ:TSBX) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership. Does the MarketBeat Community favor TSBX or PLUR? Turnstone Biologics received 4 more outperform votes than Pluri when rated by MarketBeat users. CompanyUnderperformOutperformTurnstone BiologicsOutperform Votes444.44% Underperform Votes555.56% PluriN/AN/A Does the media prefer TSBX or PLUR? In the previous week, Pluri had 4 more articles in the media than Turnstone Biologics. MarketBeat recorded 5 mentions for Pluri and 1 mentions for Turnstone Biologics. Pluri's average media sentiment score of 0.23 beat Turnstone Biologics' score of 0.00 indicating that Pluri is being referred to more favorably in the news media. Company Overall Sentiment Turnstone Biologics Neutral Pluri Neutral Is TSBX or PLUR more profitable? Turnstone Biologics has a net margin of 0.00% compared to Pluri's net margin of -3,551.49%. Turnstone Biologics' return on equity of -105.99% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Turnstone BiologicsN/A -105.99% -87.27% Pluri -3,551.49%-2,778.13%-83.61% Which has preferable earnings and valuation, TSBX or PLUR? Pluri has lower revenue, but higher earnings than Turnstone Biologics. Pluri is trading at a lower price-to-earnings ratio than Turnstone Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTurnstone Biologics$19.31M0.42-$55.20M-$3.07-0.11Pluri$678K57.38-$20.89M-$5.60-0.99 Do insiders and institutionals have more ownership in TSBX or PLUR? 52.5% of Turnstone Biologics shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 32.1% of Turnstone Biologics shares are held by insiders. Comparatively, 10.2% of Pluri shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts rate TSBX or PLUR? Turnstone Biologics presently has a consensus price target of $0.45, suggesting a potential upside of 28.57%. Given Turnstone Biologics' stronger consensus rating and higher probable upside, analysts plainly believe Turnstone Biologics is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Turnstone Biologics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Pluri 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, TSBX or PLUR? Turnstone Biologics has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Pluri has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500. SummaryTurnstone Biologics beats Pluri on 10 of the 16 factors compared between the two stocks. Get Turnstone Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for TSBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TSBX vs. The Competition Export to ExcelMetricTurnstone BiologicsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.10M$2.91B$5.44B$7.80BDividend YieldN/A1.91%5.43%4.31%P/E Ratio-0.1129.2222.1418.40Price / Sales0.42481.28389.71101.29Price / CashN/A168.6838.2034.62Price / Book0.083.036.664.18Net Income-$55.20M-$72.17M$3.21B$247.71M7 Day Performance6.06%9.36%6.21%6.61%1 Month Performance-12.50%-3.64%-2.82%-2.21%1 Year Performance-87.32%-21.09%16.44%4.68% Turnstone Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TSBXTurnstone Biologics2.0488 of 5 stars$0.35+9.7%$0.45+28.6%-87.9%$8.10M$19.31M-0.1182PLURPluri1.0049 of 5 stars$4.39+1.2%N/A+13.5%$30.72M$678,000.00-0.78150INKTMiNK Therapeutics3.2324 of 5 stars$7.68+5.7%$37.50+388.6%-11.6%$30.44MN/A-1.9730Positive NewsGap DownMRNSMarinus Pharmaceuticals1.8974 of 5 stars$0.55-0.2%$4.79+771.6%-61.3%$30.32M$30.99M-0.22110ALXOALX Oncology3.0512 of 5 stars$0.57+0.1%$4.14+630.2%-96.8%$30.27MN/A-0.1940News CoverageGap DownFGENFibroGen4.255 of 5 stars$0.30+3.9%$10.00+3,255.7%-69.2%$30.07M$29.62M-0.24570Analyst ForecastGap DownATHEAlterity Therapeutics1.8224 of 5 stars$3.36-2.8%$12.00+257.7%+54.0%$29.97MN/A0.0010Positive NewsALGSAligos Therapeutics3.6089 of 5 stars$4.90+6.1%$70.00+1,328.6%-73.3%$29.96M$3.95M-0.3790ESLAEstrella Immunopharma2.1895 of 5 stars$0.82+3.3%$16.00+1,851.2%-3.8%$29.66MN/A-3.15N/AGap UpALLKAllakos4.1475 of 5 stars$0.33+0.6%$2.00+511.6%-67.7%$29.50MN/A-0.16190BRNSBarinthus Biotherapeutics2.4335 of 5 stars$0.73+2.7%$5.17+608.7%-66.1%$29.41M$14.97M-0.49107 Related Companies and Tools Related Companies Pluri Competitors MiNK Therapeutics Competitors Marinus Pharmaceuticals Competitors ALX Oncology Competitors FibroGen Competitors Alterity Therapeutics Competitors Aligos Therapeutics Competitors Estrella Immunopharma Competitors Allakos Competitors Barinthus Biotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TSBX) was last updated on 4/26/2025 by MarketBeat.com Staff From Our Partners2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Turnstone Biologics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Turnstone Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
